European Association for Haemophilia and Allied Disorders

2nd Congress in Munich

Programme

Thursday 26th February 2009

09.00  Registration and coffee

11.00  Welcome  
W. Schramm

EAHAD: an update  
C. A. Ludlam

11.20  The Hemophilia and Thrombosis Society of North America (HTRS): Past accomplishments, present activities and future directions  
P. Kouides

11.40  Potential for transatlantic collaboration in haemophilia research - a view from the National Heart, Lung, and Blood Institute  
K. Hoots

12.00  European Haemophilia Safety Surveillance System (EUHASS): an update  
M. Makris

12.30  Rare Diseases Registry  
F. Peyvandi

12.45  Registry of mutations with discordant FVIII assays  
J. Oldenburg

13.00  Lunch
14.00 **Clinical and Laboratory Practice Symposium**  
Chairman: I.R. Peake  
Problems with inhibitor assays: H. Verbruggen  
The current status of orthopaedic scores: L. Heijnen  
How to handle major surgery in inhibitor patients: P. Holme J. Ingerslev, with APCC and recombinant factor VIIa  

15.30 *Break*  

16.00 Antithrombotic treatment in patients with inherited bleeding disorders: if, when and how: E. Mauser-Bunschoten  
Quality assurance in blood coagulation: S. Kitchen  

17.00 *Break*  

17.30 **EAHAD Annual General Meeting**  

19.30 *Informal dinner at Der Hofbräukeller*  

---  

**Friday 27th February 2009**  

8.30 **European Research Groups**  
Chairman: P.M. Mannucci  
The EU VWD Co-operative group: I.R. Peake  
vWD Type 3 Study: A.B. Federici  
Immune monitoring of haemophilia A patients undergoing ITI: an amendment to the ObsITI study: S. Lacroix-Desmazes  
CHAVI 014: Investigation of the genetic basis of resistance to HIV-1 infection in exposed but uninfected people with haemophilia A: L. Dorrell  
Open discussion on future collaborative research projects
10.0  
**Break**

10.30  
**Lecture**  
Chairman: J. Ingerslev  
The ESCHQOL study: an update  
W. Schramm

11.0  
**Debate:**  
Chairman: M. van den Berg  
Cumulative incidence of inhibitors: is it influenced by type of replacement therapy in previously untreated boys with severe haemophilia A?  
No  
J. Astermark  
Yes  
A. Gringeri

12.00  
**Lunch**

13.00  
**Symposium**  
Chairman: C. Negrier  
Primary prophylaxis in severe haemophilia: which is the optimal regimen?  
P. Petrini  
Obstetric and gynaecological problems in women with inherited bleeding disorders  
F. Peyvandi  
Use of porcine factor VIII in inhibitor patients: revisited  
K. Hoots

14.30  
**Debate**  
Chairman: B.T. Colvin  
International clinical trials are the best way to improve global haemophilia care  
No  
A Iorio  
Yes  
J Windyga

15.30  
**Close**